Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals' stock has been influenced by Q4 2025 and Q1 2026 earnings reports, which highlighted strong Rezdiffra sales growth and patient expansion, with Q1 2026 net sales reaching $311.3 million, a 127% year-over-year increase. The company also reported a wider net loss in Q1 2026 due to increased operating expenses. Madrigal announced an exclusive global licensing agreement for six preclinical siRNA programs and added a clinical-stage siRNA asset targeting a mutation in the PNPLA3 gene to its pipeline. Evercore ISI Group maintained an "Outperform" rating for MDGL but slightly lowered its price target from $652 to $649. MDGL's stock has traded between a low of $265.00 and a high of $615.00 over the past 52 weeks, and as of May 5, 2026, the share price was $501.36.

Madrigal Pharmaceuticals has observed a "Q1 effect" from insurance resets impacting new patient additions. This suggests that at the beginning of the calendar year, factors related to insurance coverage and patient deductibles may influence the rate at which new patients start treatment with Rezdiffra. Despite this, management has indicated that the market dynamics remain favorable for long-term growth.

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for metabolic dysfunction-associated steatohepatitis (MASH). Their flagship product is Rezdiffra (resmetirom), the first FDA and European Commission approved medication for adults with MASH and moderate to advanced liver fibrosis. Madrigal is also expanding its pipeline with ervogastat, an oral DGAT-2 inhibitor in Phase 2 development, and six preclinical siRNA programs, as well as MGL-2086, an oral GLP-1 receptor agonist.

Madrigal Pharmaceuticals is headquartered in West Conshohocken, Pennsylvania, United States. The company has a significant presence in both the United States and Europe, particularly with the approval and commercialization of Rezdiffra in these regions.

Madrigal Pharmaceuticals has cultivated a strong brand reputation due to the FDA and European Commission approvals of Rezdiffra as the first treatment for MASH with moderate to advanced fibrosis. Rezdiffra has achieved "blockbuster status" with over $1.1 billion in net sales over the past 12 months, with over 42,250 patients on Rezdiffra as of March 31, 2026. The company's strategic expansion of its MASH pipeline further enhances its reputation.

Madrigal Pharmaceuticals has a diverse ownership structure, with significant holdings by institutional investors, individual insiders, and retail investors. Major institutional owners include Baker Bros. Advisors Lp, Rtw Investments, Lp, and Vanguard Group Inc. Major individual owners include Bruce Kovner, Felix Baker, and Rebecca Taub.